Heron Therapeutics announces commercial leadership changes: Poyhonen, Mathews depart; Grillot appointed VP

HERON THERAPEUTICS, INC. /DE/

John Poyhonen ceases as President and Chief Commercial Officer effective April 30, 2023.
Michael Mathews ceases as SVP Commercial, Acute Care effective April 30, 2023.
Jason Grillot appointed VP Sales and Marketing, Acute Care effective April 24, 2023.
Grillot granted 350,000 stock options with 4-year vesting as material inducement.
CEO Craig Collard will oversee commercial organization after departures.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Mathews

Senior Vice President Commercial, Acute Care

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2023-04-30
Filed: April 20, 2023, 7:59 PM ET

Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.

Appointed

Jason Grillot

Vice President, Sales and Marketing, Acute Care

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2023-04-24
Filed: April 20, 2023, 7:59 PM ET

Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.

Departed

John Poyhonen

President and Chief Commercial Officer

HRTX · HERON THERAPEUTICS, INC. /DE/

Effective: 2023-04-30
Filed: April 20, 2023, 7:59 PM ET

Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Mathews departed as Senior Vice President Commercial, Acute Care at HERON THERAPEUTICS, INC. /DE/.

Action: cease to serve
Role: Senior Vice President Commercial, Acute Care

Exact text from the filing

Also effective April 30, 2023, Michael Mathews will cease to serve as the Senior Vice President Commercial, Acute Care of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Grillot was appointed as Vice President, Sales and Marketing, Acute Care at HERON THERAPEUTICS, INC. /DE/.

Action: join
Role: Vice President, Sales and Marketing, Acute Care

Exact text from the filing

Additionally, effective April 24, 2023, Jason Grillot will join the Company as Vice President, Sales and Marketing, Acute Care.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Poyhonen departed as President and Chief Commercial Officer at HERON THERAPEUTICS, INC. /DE/.

Action: cease to serve
Role: President and Chief Commercial Officer

Exact text from the filing

Effective as of April 30, 2023, John Poyhonen will cease to serve as the President and Chief Commercial Officer of Heron Therapeutics, Inc. (the “Company”).

View on SEC.gov

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-013583

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.